Lobular carcinoma in situ (LCIS) of the right breast is a non-invasive breast cancer characterized by abnormal cell growth in the lobules of the breast. While LCIS is not considered a true breast cancer, it is a marker for increased risk of developing invasive breast cancer in the future. Accurate coding with ICD-10 Code D05.01 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring that patients receive appropriate surveillance and management.
ICD-10 Code D05.01 specifically denotes lobular carcinoma in situ of the right breast. This condition involves the proliferation of atypical cells within the lobules, which can indicate a higher risk for subsequent invasive breast cancer. This code should be utilized in clinical documentation and billing when diagnosing patients with LCIS to ensure accurate representation of the patient's condition and to facilitate appropriate management strategies.
Lobular carcinoma in situ of the right breast is a non-invasive neoplasm that arises from the lobular epithelium. It is characterized by small, non-cohesive clusters of atypical cells that fill the lobules. Although it does not typically present with symptoms, it requires careful monitoring due to its association with an increased risk of developing invasive breast cancer.
ICD-10 Code D05.01 is utilized in SOAP notes to document the diagnosis of lobular carcinoma in situ of the right breast. This code plays a critical role in capturing the patient's clinical status, guiding treatment decisions, and ensuring accurate billing in both acute and chronic care settings.
In SOAP notes, ICD-10 Code D05.01 connects subjective reports of patient history and objective clinical findings to a formal diagnosis of lobular carcinoma in situ of the right breast. This code is essential for maintaining continuity of care, supporting billing processes, and meeting EHR documentation standards.
Management of lobular carcinoma in situ of the right breast typically involves careful monitoring rather than immediate invasive treatment. Surgical intervention may be considered based on individual risk factors.


HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.
Learn moreICD-10 Code D05.01 is crucial in medical billing, particularly in hospital and outpatient settings, to ensure accurate reimbursement for services related to lobular carcinoma in situ of the right breast.
| CPT Code | Description |
|---|---|
| 99213 | Established patient office visit, Level 3 |
| 88305 | Pathology examination of tissue, Level 4 |
| 76000 | Mammography, bilateral, screening |
Common Questions About Using ICD-10 Code D05.01 for Lobular carcinoma in situ of right breast
What is lobular carcinoma in situ?
Lobular carcinoma in situ (LCIS) is a non-invasive condition where abnormal cells grow in the lobules of the breast. While it is not considered breast cancer, it indicates an increased risk for developing invasive breast cancer in the future.
How is lobular carcinoma in situ diagnosed?
LCIS is typically diagnosed through imaging studies such as mammograms and confirmed via biopsy. It is often found incidentally during evaluations for other breast conditions.
What are the treatment options for lobular carcinoma in situ?
Management of LCIS usually involves regular monitoring and surveillance rather than immediate treatment. In some cases, risk-reducing strategies, including prophylactic mastectomy, may be discussed.
Is lobular carcinoma in situ hereditary?
While LCIS itself is not hereditary, individuals with a family history of breast cancer may have a higher risk of developing both LCIS and invasive breast cancer. Genetic counseling may be recommended.
Clinical Notes
SOAP notes
DAP notes
AI medical notes